Neuromyelitis Optica Spectrum Disorders Clinical Trials

9 recruiting

Neuromyelitis Optica Spectrum Disorders Trials at a Glance

11 actively recruiting trials for neuromyelitis optica spectrum disorders are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Tianjin, Changsha, and Changsha. Lead sponsors running neuromyelitis optica spectrum disorders studies include Cedars-Sinai Medical Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Assistance Publique Hopitaux De Marseille.

Browse neuromyelitis optica spectrum disorders trials by phase

Treatments under study

About Neuromyelitis Optica Spectrum Disorders Clinical Trials

Looking for clinical trials for Neuromyelitis Optica Spectrum Disorders? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neuromyelitis Optica Spectrum Disorders trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neuromyelitis Optica Spectrum Disorders clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 4

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital198 enrolled1 locationNCT07420296
Recruiting
Phase 1

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders
Tongji Hospital69 enrolled1 locationNCT06620809
Recruiting
Early Phase 1

Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

Multiple SclerosisAlzheimer DiseaseParkinson Disease+2 more
Assistance Publique Hopitaux De Marseille700 enrolled1 locationNCT07202494
Recruiting
Phase 1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Myasthenia GravisSystemic Lupus Erythematosus (SLE)Multiple Sclerosis (MS)+3 more
RenJi Hospital30 enrolled1 locationNCT06249438
Recruiting
Not Applicable

Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders
Third Affiliated Hospital, Sun Yat-Sen University144 enrolled1 locationNCT06763848
Recruiting
Not Applicable

Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.

Multiple SclerosisNeuromyelitis Optica Spectrum DisordersMOGAD
Fondazione Policlinico Universitario Agostino Gemelli IRCCS50 enrolled1 locationNCT06865274
Recruiting
Phase 2Phase 3

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd132 enrolled51 locationsNCT06413654
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)

Neuromyelitis Optica Spectrum Disorders
Guangzhou JOYO Pharma Co., Ltd35 enrolled1 locationNCT06697535
Recruiting

MS-ResearchBiomarkerS

Neurologic DisorderMultiple SclerosisClinically Isolated Syndrome+8 more
Cedars-Sinai Medical Center1,000 enrolled1 locationNCT05204459
Recruiting

Assisted Reproductive Technology in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ARTiMS) study. A prospective, longitudinal study.

PregnancyMultiple SclerosisNeuromyelitis Optica Spectrum Disorders
John Hunter Hospital of the Hunter New England Local Health District25 enrolled1 locationACTRN12623001310651